Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 7 years, with Q4 2025 value amounting to $90000.0.

  • Agios Pharmaceuticals' Other Non-Current Liabilities fell 8977.27% to $90000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $90000.0, marking a year-over-year decrease of 8977.27%. This contributed to the annual value of $90000.0 for FY2025, which is 8977.27% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $90000.0 for Q4 2025, which was down 8977.27% from $90000.0 recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Other Non-Current Liabilities registered a high of $3.3 million during Q4 2022, and its lowest value of $90000.0 during Q3 2025.
  • Over the past 4 years, Agios Pharmaceuticals' median Other Non-Current Liabilities value was $1.2 million (recorded in 2023), while the average stood at $1.0 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 957.35% in 2023, and later plummeted by 9221.45% in 2025.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then plummeted by 64.75% to $1.2 million in 2023, then fell by 23.88% to $880000.0 in 2024, then tumbled by 89.77% to $90000.0 in 2025.
  • Its Other Non-Current Liabilities was $90000.0 in Q4 2025, compared to $90000.0 in Q3 2025 and $101000.0 in Q2 2025.